CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
TargImmune is developing innovative immunotherapy drugs aimed at treating aggressive cancers. By utilizing a targeted delivery system for RNA-analogue treatments, the project seeks to improve efficacy and reduce side effects for a broader range of patients.
In spite of enormous medical progress, aggressive forms of cancer remain one of the leading causes of death across the globe.
Metastasized prostate, lung, breast and colon cancer account for a combined mortality of approximately 0,8 M lives in Europe per year.
Immunotherapies, activating patient’s own immune system to target and destroy tumor cells, have shown enormous promise in the treatment of metastatic forms of cancer, creating a huge market with a €100B potential in 2022.
However, these dr…
TARGIMMUNE THERAPEUTICS AG
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
